Abstract

Research Article

COVID-19 immunologic and toxicological implication: Innate immune sensor and immune escape

Luisetto M*, Farhan Ahmad Khan, Khaled Edbey, Gamal Abdul Hamid, Mashori GR, Nili BA, Fiazza C, YesvI R and Latishev Yu O

Published: 25 March, 2021 | Volume 5 - Issue 1 | Pages: 001-017

Related COVID-19 and new Variant and treatment like vaccine it is relevant to deeply verify the immunologic implication and in a special way regarding the innate immune sensor system and the evasion of the immune system.

This can be crucial to search for new strategies to fight this severe disease under a Toxicology-antidotes point of view.

The rapid emergence of a new variant is under study by researchers because some of these show different responses to antibodies as reported in literature (vaccine efficacy?).

In this article after a review part it is submitted a collection of hypothesis of solution to contrast COVID-19.

Spread and mortality and project hypothesis.

A new toxicological approach also in a viral respiratory disease can be a novelty to adequately fight this severe condition and this focusing not only towards specific immunity but also a specific measures.

A toxicological approach in drug- vaccine like products designing makes it possible to get the clinical outcomes needed.

Read Full Article HTML DOI: 10.29328/journal.apps.1001025 Cite this Article Read Full Article PDF

Keywords:

COVID-19; Cytokine storm; Endogenous toxicology; Pathology; Therapeutic strategy; Immune system; Innate immune system; Antidotes; Chemical physical coronavirus surface properties; Tumor lysis syndrome

References

  1. Catanzaro M, Fagiani F, Racchi M. Corsini E, Govoni S, et al. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Sig Transduct Target Ther. 2020; 5: 84. PubMed: https://pubmed.ncbi.nlm.nih.gov/32467561/
  2. Mangalmurti N, Hunter CA. Cytokine Storms: Understanding COVID-19. Immunity. 2020; 53: 19–25. PubMed: https://pubmed.ncbi.nlm.nih.gov/32610079/
  3. Mustafa MI, et al. Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors. Mediators of Inflamm. 2020; 2020: 1-7. PubMed: https://pubmed.ncbi.nlm.nih.gov/33029105/
  4. Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020; 55: 105982. PubMed: https://pubmed.ncbi.nlm.nih.gov/32305588/
  5. Fatima U, Rizvi SSA, Fatima S, Hassan MI. Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin. J Interferon Cytokine Res. 2020; 469-471. PubMed: https://pubmed.ncbi.nlm.nih.gov/32881593/
  6. Pelaia C, Tinello C, Vatrella A, De Sarro G, Pelaia G. Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications. Therapeutic advances in respiratory disease. 2020; 14: 1753466620933508. PubMed: https://pubmed.ncbi.nlm.nih.gov/32539627/
  7. Tang Y, Liu J, Zhang D, Xu Z, Ji J, et al. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Front Immunol. 2020; 11: 1708. PubMed: https://pubmed.ncbi.nlm.nih.gov/32754163/
  8. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, et al. How COVID-19 induces cytokine storm with high mortality. Inflammation and Regeneration. 2020; 40: 37. PubMed: https://pubmed.ncbi.nlm.nih.gov/33014208/
  9. Mangalmurti N, Hunter CA. Cytokine Storms: Understanding COVID-19. Immunity. 2020; 53: 19–25. PubMed: https://pubmed.ncbi.nlm.nih.gov/32610079/
  10. Ortolani C, Pastorello EA. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost? Clin Mol Allergy. 2020; 18: 17.
  11. Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020; 2: e428–e436. PubMed: https://pubmed.ncbi.nlm.nih.gov/32835246/
  12. Hosseini A, Hashemi V, Shomali N, Asghari F, Gharibi T, et al. Innate and adaptive immune responses against coronavirus. Biomed Pharmacother. 2020; 132: 110859. PubMed: https://pubmed.ncbi.nlm.nih.gov/33120236/
  13. Riva G, Nasillo V, Tagliafico E, et al. COVID-19: more than a cytokine storm. Crit Care. 2020; 24: 549.
  14. Chen N, Xia P, Li S, Zhang T, Wang TT, et al. RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life. 2017; 69: 297-304. PubMed: https://pubmed.ncbi.nlm.nih.gov/28374903/
  15. Theofilopoulos AN, Gonzalez-Quintial R, Lawson BR, Koh YT, Stern ME, et al. Sensors of the innate immune system: their link to rheumatic diseases. Nat Rev Rheumatol. 2010; 6: 146–156. PubMed: https://pubmed.ncbi.nlm.nih.gov/20142813/
  16. Li G, Fan Y, Lai Y, Han T, Li Z, et al. Coronavirus infections and immune responses. J Med Virol. 2020; 92: 424-432. PubMed: https://pubmed.ncbi.nlm.nih.gov/31981224/
  17. Nelemans T, Kikkert M. Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections. Viruses. 2018; 11: 961. PubMed: https://pubmed.ncbi.nlm.nih.gov/31635238/
  18. Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Front Immunol. 2020; 11: 1949. PubMed: https://pubmed.ncbi.nlm.nih.gov/32849654/
  19. Clarissa C, Tellier M, Lu F, Maleki-Toyserkani S, Jones R, et al. Innate immunology in COVID-19—a living review. Part I: viral entry, sensing and evasion. Oxford Open Immunol. 2020; 1: iqaa004.
  20. Nelemans T, Kikkert M. Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections. Viruses. 2019; 11: 961. PubMed: https://pubmed.ncbi.nlm.nih.gov/31635238/
  21. Sariol A, Perlman S. Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity. 2020; 53: 248–263. PubMed: https://pubmed.ncbi.nlm.nih.gov/32717182/
  22. Castro RF, Perlman S. CD8+ T-cell epitopes within the surface glycoprotein of a neurotropic coronavirus and correlation with pathogenicity. J Virol. 1985; 69: 8127–8131. PubMed: https://pubmed.ncbi.nlm.nih.gov/7494335/
  23. Li Q, Nie J, Wu J, Zhang L, Ding R, et al. No higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants. Cell. 2021. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901273/
  24. Knezevic I, Liu MA, Peden K, Zhou T, Kang HN. Development of mRNA Vaccines: Scientific and Regulatory Issues. Vaccines. 2021; 9: 81. PubMed: https://pubmed.ncbi.nlm.nih.gov/33498787/
  25. Wang P, Nair MS, Liu L, Iketani S, Luo Y, et al. Antibody Resistance of SARS-CoV-2 Variants. 2021; B.1.351 and B.1.1.7. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852271/
  26. Rani PR, Imran M, Lakshmi JV, Jolly B, Jain A, et al. Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape. OSF Preprints .2021.
  27. Al-Sayah MH. Chemical disinfectants of COVID-19: an overview. J Water Health. 2020; 18: 843-848. PubMed: https://pubmed.ncbi.nlm.nih.gov/33095205/
  28. Luisetto M. Chemico- Physicals Properties Of Coronavirus Affecting Airborne Trasmissibility. Int Invent Scientific J. 2021; 05.
  29. Jin P, Li J, Pan H, Wu Y, Zhu F. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Sig Transduct Target Ther. 2021; 6: 48.
  30. Pal A, Squitti R, Picozza M, Pawar A, Rongioletti M, et al. Zinc and COVID-19: Basis of Current Clinical Trials. Biol Trace Elem Res. 2020; 1-11. PubMed: https://pubmed.ncbi.nlm.nih.gov/33094446/
  31. Carr AC, Rowe S. The Emerging Role of Vitamin C in the Prevention and Treatment of COVID-19. Nutrients. 2020; 12: 3286. PubMed: https://pubmed.ncbi.nlm.nih.gov/33121019/
  32. Cutolo M, Paolino S, Smith V. Evidences for a protective role of vitamin D in COVID-19. RMD open. 2020; 6: e001454. PubMed: https://pubmed.ncbi.nlm.nih.gov/33372031/
  33. Milane L, Amiji M. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Deliv Transl Res. 2021; 1–7. PubMed: https://pubmed.ncbi.nlm.nih.gov/33512669/
  34. Sententia TAR Lazio ITALY - Sezione Terza Quater con Ordinanza del 2-4. 2021.
  35. Nakamura M, Oda S, Sadahiro T, Hirayama Y, Tateishi Y, et al. The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF). Case Reports Transfus Apher Sci. 2009; 40: 41-47. PubMed: https://pubmed.ncbi.nlm.nih.gov/19109071/
  36. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, et al. Cytokine release syndrome. J Immunother Cancer. 2018; 6: 56. PubMed: https://pubmed.ncbi.nlm.nih.gov/29907163/

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Figure 1

Figure 7

Figure 1

Figure 8

Figure 1

Figure 9

Figure 1

Figure 10

Figure 1

Figure 11

Figure 1

Figure 12

Figure 1

Figure 13

Figure 1

Figure 14

Figure 1

Figure 15

Similar Articles

Recently Viewed

  • Environmental Factors Affecting the Concentration of DNA in Blood and Saliva Stains: A Review
    Divya Khorwal*, GK Mathur, Umema Ahmed and SS Daga Divya Khorwal*, GK Mathur, Umema Ahmed, SS Daga. Environmental Factors Affecting the Concentration of DNA in Blood and Saliva Stains: A Review. J Forensic Sci Res. 2024: doi: 10.29328/journal.jfsr.1001057; 8: 009-015
  • Why Down-managing Backlog Forensic DNA Case Entries Matters
    JH Smith* and JS Horne JH Smith*, JS Horne. Why Down-managing Backlog Forensic DNA Case Entries Matters. J Forensic Sci Res. 2024: doi: 10.29328/journal.jfsr.1001056; 8: 001-008
  • Scintigraphic non-invasive diagnosis of amyloid cardiomyopathy
    Laroussi Mohamed-Salem*, Tomás E Rodríguez-Locarno, Tatiana Moreno-Monsalve, Isabel Castellón-Sánchez, José F Contreras-Gutiérrez and Antonia Claver-Valderas Laroussi Mohamed-Salem*,Tomás E Rodríguez-Locarno,Tatiana Moreno-Monsalve,Isabel Castellón-Sánchez,José F Contreras-Gutiérrez ,Antonia Claver-Valderas. Scintigraphic non-invasive diagnosis of amyloid cardiomyopathy. J Cardiol Cardiovasc Med. 2019: doi: 10.29328/journal.jccm.1001058; 4: 156-158
  • Anomalies of coronary artery origin: About two cases
    Dioum M*, Sarr EM, Manga S, Mingou JS, Diack A, Diop AD, Bindia D, Diagne PA, Sarr AN and Diop IB Dioum M*,Sarr EM,Manga S,Mingou JS,Diack A,Diop AD,Bindia D,Diagne PA,Sarr AN,Diop IB. Anomalies of coronary artery origin: About two cases. J Cardiol Cardiovasc Med. 2019: doi: 10.29328/journal.jccm.1001051; 4: 117-119
  • Late discover of a traumatic cardiac injury: Case report
    Benlafqih C, Bouhdadi H*, Bakkali A, Rhissassi J, Sayah R and Laaroussi M Benlafqih C,Bouhdadi H*,Bakkali A,Rhissassi J,Sayah R,Laaroussi M. Late discover of a traumatic cardiac injury: Case report. J Cardiol Cardiovasc Med. 2019: doi: 10.29328/journal.jccm.1001048; 4: 100-102

Read More

Most Viewed

Read More

Help ?